Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04494360 · ClinicalTrials.gov registry record
Study to Estimate How Common it is to Have Genetic Variants Associated With NAFLD
A clinical trial, sponsored by Janssen Research & Development.
- Completed
- Registry status
- 830
- Enrollment target
NCT04494360: Completed study, sponsored by Janssen Research & Development.
NCT04494360 is a clinical trial that has completed, run by Janssen Research & Development. The registered enrollment target is 830 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04494360 has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- 830 participants
- Enrollment target
Study Summary
The purpose of this study is to estimate the prevalence of genetic variants associated with liver disease in participants who are known, or are likely to have NAFLD.
Primary Outcome
Genotyping for known mutations associated with NAFLD will be conducted and the prevalence in the overall population enrolled will be calculated.
Interventions
- OTHER No intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 830 participants |
| Start Date | 2020-08-07 |
| Est. Completion | 2022-10-10 |
What the finished NCT04494360 record still lists
NCT04494360 is an observational study that tracks outcomes without assigning an intervention. The registered 830 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which No intervention is the first listed.
NCT04494360 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04494360 about?
NCT04494360 is a clinical study titled "Study to Estimate How Common it is to Have Genetic Variants Associated With NAFLD". The purpose of this study is to estimate the prevalence of genetic variants associated with liver disease in participants who are known, or are likely to have NAFLD.
What is the current status of trial NCT04494360?
This trial is currently completed. The enrollment target is 830 participants. The study started on 2020-08-07. Estimated completion is 2022-10-10.
What interventions are being tested in trial NCT04494360?
The interventions under investigation include: No intervention (OTHER).
Who is sponsoring clinical trial NCT04494360?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05067283 · 830 participants · Phase 1
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
- NCT06592924 · 830 participants · Phase 3
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
- NCT06868277 · 830 participants · Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- NCT06910553 · 832 participants
IBD Pregnancy Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI